Bristol Myers Squibb's Phase 3 Checkmate -67T Noninferiority Trial Of Subcutaneous Opdivo (Nivolumab) Compared To Intravenous Opdivo For Clear Cell Renal Cell Carcinoma Met Its Co-primary Pharmacokinetics Endpoints, Key Secondary Endpoint
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb's Phase 3 Checkmate -67T noninferiority trial of subcutaneous Opdivo (Nivolumab) compared to intravenous Opdivo for clear cell renal cell carcinoma met its co-primary pharmacokinetics endpoints, key secondary endpoint.
October 19, 2023 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb's successful Phase 3 trial of Opdivo indicates a positive development in the company's cancer treatment portfolio.
The successful trial of Opdivo is a positive development for Bristol Myers Squibb. It indicates the company's progress in developing effective treatments for cancer, which could potentially lead to increased revenues and a stronger market position in the future. This is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100